Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ceftriaxone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.80 |
| ▸ | PGR | P06401 | 3/20 | 0.80 |
| ▸ | PPARG | P37231 | 2/20 | 0.80 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.80 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.80 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.80 |
| ▸ | DAO | P14920 | 1/20 | 0.80 |
| ▸ | SNCA | P37840 | 1/20 | 0.80 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.78 |
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | APEX1 | P27695 | 3/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | RECQL | P46063 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ceftriaxone SCHEMBL2006477 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL8619948 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL8378294 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL2224183 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL4897101 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL30307091 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL23354 | 1.00 | NR1I2 (0.80) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL4885115 | 0.99 | NR1I2 (0.79) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL22635993 | 0.99 | NR1I2 (0.79) | NR1I2PGRPPARGSLC22A6SLC22A8 | |
| Ceftriaxone SCHEMBL150106 | 0.99 | NR1I2 (0.79) | NR1I2PGRPPARGSLC22A6SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008041100-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CEPHALOSPORIN ANTIBIOTICS | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-04-10 | — | — | WO | claimed |
| EP-0628561-B1 | Process for preparing cephalosporin compounds from reactive organic acid derivatives | LUCKY LTD (KR) | 1997-09-03 | — | — | EP | claimed |
| EP-0628561-A1 | Process for preparing cephalosporin compounds from reactive organic acid derivatives | LUCKY LTD. (KR) | 1994-12-14 | — | — | EP | claimed |
| US-8778873-B2 | Parenteral combination therapy for infective conditions with drug resistant bacterium | VENUS REMEDIES LIMITED (IN) | 2014-07-15 | — | — | US | disclosed |
| US-20110257079-A1 | Parenteral Combination Therapy for Infective Conditions With Drug Resistant Bacterium | VENUS REMEDIES LIMITED (IN) | 2011-10-20 | — | — | US | disclosed |
| US-7960337-B2 | Synergistic formulation containing such as vancomycin and ceftriaxone; broad spectrum gram negative and gram positive effective agents | Venues Remedies Limited (IN) | 2011-06-14 | — | — | US | disclosed |
| US-20080188403-A1 | Parenteral Combination Therapy For Infective Conditions With Drug Resistant Bacterium | VENUS REMEDIES LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| US-6552186-B2 | Ceftrixone, cefotaxime or derivatives | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2003-04-22 | — | — | US | disclosed |
| US-20020128469-A1 | Beta-lactam production | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2002-09-12 | — | — | US | disclosed |
| EP-1169324-A1 | BETA-LACTAM PRODUCTION | BIOCHEMIE Gesellschaft m.b.H. (AT) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000063214-A1 | BETA-LACTAM PRODUCTION | BIOCHEMIE GESELLSCHAFT M B H (AT) | 2000-10-26 | — | — | WO | disclosed |
| EP-0628561-B1 | Process for preparing cephalosporin compounds from reactive organic acid derivatives | LUCKY LTD (KR) | 1997-09-03 | — | — | EP | disclosed |
| EP-0628561-A1 | Process for preparing cephalosporin compounds from reactive organic acid derivatives | LUCKY LTD. (KR) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128469-A1 | Beta-lactam production | MRPL21, COASY, Q6ZSR9 | NR1I2 558/4885PGR 4613/4885PPARG 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.